Why I Can’t Stop Buying This “Boring” Chipmaker With Game Changing Upside

Photo of Alex Sirois
By Alex Sirois Published

Quick Read

  • Hock Tan guided AVGO to $56 billion in AI revenue for 2026 and over $100 billion for fiscal 2027, with Q2 bookings hitting $30 billion.

  • Unlike NVDA, AMD, or MRVL, AVGO pairs deep AI exposure with 15 consecutive dividend increases and named gigawatt-scale commitments from Google, Meta, and OpenAI.

  • With 44 analyst buy ratings and zero sells, Broadcom's $30 billion Q2 backlog points to a multi-year infrastructure build-out, not a short-term demand spike.

  • This lithium producer surpassed a $1B private valuation, joining some of America’s most powerful startups. Now you can invest in EnergyX alongside global giants like General Motors, but only through July 16. (sponsor)

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Why I Can’t Stop Buying This “Boring” Chipmaker With Game Changing Upside

© krystiannawrocki / E+ via Getty Images

I keep hitting the buy button on Broadcom (NASDAQ:AVGO | AVGO Price Prediction), and every quarter Hock Tan gives me a fresh reason to do it again. I own the boring chipmaker, keep adding on weakness, and the last four quarters keep telling me I am not early enough.

The thesis: every AI cluster needs custom accelerators and Ethernet fabric before GPUs can talk to each other. Broadcom sells that wiring under multi-year commitments that turn a volatile silicon cycle into something closer to a toll road.

The Data Doing the Arguing

AI semiconductor revenue hit $10.80 billion in Q2 FY2026, up 143% year over year, and Tan guided Q3 to $16 billion, up over 200% year on year. He put full-year 2026 AI revenue at $56 billion and fiscal 2027 at in excess of $100 billion. Q2 AI bookings landed at over $30 billion against $10.8 billion shipped, which is why he said visibility “extends into 2028.”

Q2 free cash flow was $10.26 billion, or 46% of revenue. Adjusted EBITDA margin ran at 69%. Operating income rose 85.07% year over year on 48% revenue growth. Cash on the balance sheet climbed to $19.63 billion, up 107.22% year over year, while total liabilities fell 3.76%.

The dividend was raised 10% in Q4 FY2025 to $0.65 per share, marking 15 consecutive annual increases since fiscal 2011. A fresh $10 billion buyback was authorized in March 2026, and management already put $7.8 billion of that to work in Q1. Eight straight EPS beats round it out.

Why Not the Obvious Names

Why not just pile into NVIDIA (NASDAQ:NVDA) or Advanced Micro Devices (NASDAQ:AMD) or Marvell Technology (NASDAQ:MRVL)? First, none pair AI exposure with a 15-year rising dividend the way Broadcom does, and my retirement account needs the income compounding. Second, Broadcom is the counterparty for custom silicon hyperscalers build instead of buying merchant GPUs, with named commitments from Google, Meta, OpenAI, and Anthropic, including a 1.3-gigawatt OpenAI deployment in 2027 and a 3-gigawatt Meta program through end of 2028. Own the toll booth, and you are indifferent to which car wins the race.

The Risk I Am Not Dismissing

Concentration is real. A handful of hyperscalers drive the AI number, and the filing flags “dependence on limited number of significant customers” as a risk. What keeps me buying is the backlog shape: $30 billion of Q2 bookings and gigawatt commitments stretching into 2028 look less like a single-quarter demand pulse and more like a build-out schedule.

Insiders have been net sellers over the past 90 days. Retail chatter on the Apple extension stayed muted while the stock rose 11.28% in a week and 45.4% over the past year. Analyst consensus target sits at $523.73, with 44 buy or strong buy ratings and zero sells. I will keep buying Broadcom until Hock Tan stops raising the AI number.

Contact [email protected] for any questions or corrections.

Photo of Alex Sirois
About the Author Alex Sirois →

Alex Sirois is a financial writer with experience spanning both retail and institutional investing. He has written for InvestorPlace and held roles at BNY Mellon and Bernstein, giving him a perspective that bridges Main Street portfolios and Wall Street analysis.

Alex holds an MBA from George Washington University and has built his career across multiple industries, including e-commerce, education, and translation — a breadth of experience that informs how he breaks down complex financial topics for everyday investors. His writing is conversational, actionable, and grounded in long-term, buy-and-hold investing principles.

At 247 Wall St., Alex focuses on delivering analysis that is both accessible and useful, with a clear emphasis on helping readers make more informed decisions with their money.

Continue Reading

Top Gaining Stocks

META Vol: 40,725,136
KMX Vol: 2,287,923
WY Vol: 6,523,200
SBAC Vol: 1,443,798
NVDA Vol: 148,031,689

Top Losing Stocks

MRNA Vol: 9,166,754
CTRA Vol: 73,319,495
CRWD Vol: 9,258,683
DDOG Vol: 5,133,568
EPAM Vol: 1,164,554